Has Drew Barrymore confirmed she uses HRT?

Barrymore has confirmed she discussed HRT with her doctor and explored it as a treatment for perimenopause. She has not publicly confirmed the specific medication, formulation, or whether she is actively taking HRT at this time.

What perimenopause symptoms has Drew Barrymore described?

On her talk show and in interviews, Barrymore has described weight gain, brain fog, mood changes, and feeling "blindsided" by the intensity of the transition. These symptoms are consistent with the hormonal fluctuations documented in the SWAN longitudinal study.

Is HRT safe for women in their late 40s?

For most symptomatic women under 60 or within 10 years of menopause onset, HRT carries a favorable risk-benefit profile according to the NAMS 2017 position statement. Transdermal estradiol combined with micronized progesterone is considered the lowest-risk formulation. Individual assessment by a clinician is always required.

Why are so many women still afraid of HRT?

The 2002 WHI trial generated alarming headlines about breast cancer and heart disease risk. Later reanalysis showed those risks were concentrated in older women who started HRT well past menopause. The corrected data has been slow to reach both the public and many primary care physicians.

What alternatives to HRT exist for perimenopause symptoms?

Non-hormonal options include SSRIs/SNRIs for hot flashes (paroxetine is FDA-approved for this indication), cognitive behavioral therapy for sleep and mood symptoms, ospemifene for vaginal dryness, and fezolinetant (a neurokinin-3 receptor antagonist) approved in 2023. None match the breadth of symptom relief that systemic HRT provides.

Drew Barrymore and Women's HRT: The Documented Public Record

By HealthRX.com Medical Team

Published May 25, 2026Updated May 25, 2026Last reviewed May 25, 2026

Clinical image for Drew Barrymore and Women's HRT: The Documented Public Record Image: HealthRX.com clinical image

What Drew Barrymore Has Said Publicly

Drew Barrymore first brought menopause into mainstream daytime television by discussing her own perimenopause symptoms on The Drew Barrymore Show. In segments aired between 2022 and 2024, she described unexpected weight gain, brain fog, and emotional volatility that she attributed to hormonal changes. During a widely shared January 2023 conversation with Dr. Heather Hirsch (a menopause specialist), Barrymore told viewers she had been "blindsided" by how dramatically her body changed during perimenopause.

In a separate interview, Barrymore discussed how perimenopause symptoms overlapped with emotional patterns she initially misattributed to stress or lifestyle. She has confirmed publicly that she explored HRT as a treatment option with her physician. The specific formulation, dose, or duration of any hormone therapy she may be using has not been publicly disclosed, and the HealthRX.com Medical Team does not speculate beyond what she has stated on the record.

What makes Barrymore's disclosure significant is the platform. Daytime television reaches millions of women in the 40-to-60 demographic who are statistically most likely to be experiencing perimenopause or menopause, and many of those women report receiving little to no information from their physicians about available treatments.

The Clinical Picture: What Is Perimenopause?

Perimenopause is the transitional window before menopause (defined as 12 consecutive months without a menstrual period). It typically begins in a woman's early-to-mid 40s and can last anywhere from 4 to 10 years. During this phase, estradiol and progesterone levels fluctuate unpredictably rather than declining on a smooth curve.

The Study of Women's Health Across the Nation (SWAN), a longitudinal cohort study following over 3,000 women, documented the most common perimenopausal symptoms: vasomotor symptoms (hot flashes and night sweats) in roughly 80% of women, sleep disruption, mood disturbance, vaginal dryness, and changes in body composition. Barrymore's publicly described symptoms, including weight redistribution and cognitive fog, align with well-characterized features of the perimenopausal transition.

Hormone Replacement Therapy: Mechanism and Evidence

HRT works by supplementing the estrogen (and, when a uterus is present, progesterone) that the ovaries produce in diminishing quantities. The two primary categories:

Systemic estrogen therapy. Delivered orally, transdermally (patch, gel, spray), or via injection. Transdermal estradiol avoids hepatic first-pass metabolism and carries a lower venous thromboembolism risk compared to oral conjugated equine estrogens. Standard doses range from 0.5 mg to 2 mg oral estradiol or 25 to 100 mcg transdermal estradiol daily.

Combined estrogen-progestogen therapy. Required for women who still have a uterus to prevent endometrial hyperplasia. Micronized progesterone (100 to 200 mg oral, cyclically or continuously) is the most commonly prescribed progestogen in current practice, largely because of its favorable safety profile relative to synthetic progestins.

The 2017 North American Menopause Society (NAMS) position statement reaffirmed that HRT remains the most effective treatment for vasomotor symptoms and is appropriate for symptomatic women under age 60 or within 10 years of menopause onset. This "timing hypothesis" is central to current prescribing: initiating HRT earlier in the menopausal transition appears to carry cardiovascular benefit, while starting it well after age 60 may increase certain risks.

The WHI Context: Why So Many Women Were Told to Avoid HRT

Much of the public fear around HRT traces to the Women's Health Initiative (WHI) trial, published in 2002. The WHI reported increased breast cancer and cardiovascular events in women taking oral conjugated equine estrogen plus medroxyprogesterone acetate. The resulting media coverage was dramatic, and HRT prescriptions fell by more than 50% within two years.

What the headlines missed: the WHI enrolled predominantly older women (average age 63), many of whom were more than a decade past menopause. Subsequent reanalysis of the WHI data, stratified by age and time since menopause, showed that women who started HRT in their 50s actually had reduced all-cause mortality and coronary heart disease risk. The estrogen-only arm (for women without a uterus) showed no increase in breast cancer after 7 years of follow-up.

The practical consequence of the WHI's oversimplified messaging is that millions of symptomatic women went untreated for two decades. A 2019 survey published in Menopause found that only 7% of internal medicine residents received formal menopause training, which partly explains why so many women report being told to "just push through it."

This is the exact gap Barrymore's public discussion addresses. By describing her own confusion and eventual conversation with a menopause specialist, she gave her audience implicit permission to seek care.

Expected Benefits and Side Effect Profile

For women who are candidates for HRT, the documented benefits extend beyond hot flash reduction.

Vasomotor symptoms. HRT reduces hot flash frequency by roughly 75% compared to placebo.

Bone density. Estrogen is the single most effective agent for preventing postmenopausal bone loss. The WHI confirmed a 34% reduction in hip fractures in the HRT group.

Genitourinary syndrome of menopause (GSM). Vaginal estrogen (a local, low-dose option) is first-line therapy for vaginal dryness, dyspareunia, and recurrent urinary tract infections.

Mood and cognition. Observational data and small RCTs suggest that estradiol during early perimenopause may improve depressive symptoms, though it is not FDA-approved as an antidepressant.

Common side effects include breast tenderness, bloating, headache, and irregular bleeding during the first 3 to 6 months. These typically resolve with dose adjustment. The most serious risks, venous thromboembolism and a small absolute increase in breast cancer with combined therapy beyond 5 years, are substantially mitigated by choosing transdermal estradiol and micronized progesterone over oral conjugated estrogen and synthetic progestins.

Who Should Not Take HRT

Absolute contraindications include a history of estrogen-receptor-positive breast cancer, active liver disease, unexplained vaginal bleeding, and a history of venous thromboembolism (though transdermal estrogen may be considered case-by-case). Women with a strong family history of breast cancer should have an individualized risk-benefit discussion with their clinician.

The HealthRX.com Medical Team Take

Drew Barrymore's willingness to discuss perimenopause on national television addresses a clinical problem that published data confirms is real: most women entering menopause do not receive adequate counseling about their treatment options. The SWAN data, the WHI reanalyses, and the NAMS position statements all support that HRT is safe and effective for the majority of symptomatic women who start it within the appropriate window.

What Barrymore got right, based on her public comments, is the process. She described being confused by her symptoms, seeking out a specialist, and having a real conversation about hormones rather than dismissing the option based on outdated fear. That sequence, recognition of symptoms followed by informed medical consultation, is exactly what menopause experts recommend.

The HealthRX.com Medical Team does not know which specific HRT regimen (if any) Barrymore is currently using. That is a private medical decision. What we can say is that her public story tracks closely with the clinical evidence: perimenopause causes real, measurable physiological changes, and HRT is the most well-studied intervention for managing them.

At a glance

What's confirmed: Drew Barrymore has publicly discussed perimenopause symptoms (weight changes, brain fog, mood shifts) and confirmed she explored HRT with her doctor
What's not confirmed: The specific HRT formulation, dose, or whether she is currently using it
Clinical context: HRT remains the most effective treatment for vasomotor symptoms per the 2017 NAMS position statement, with the best risk-benefit profile when initiated before age 60 or within 10 years of menopause
Why it matters: Barrymore's platform reaches the exact demographic most likely to be undertreated for menopausal symptoms

Frequently asked questions

›

References

Santoro N, et al. "Perimenopause: from research to practice." J Women's Health. 2015. PubMed
The NAMS 2017 Hormone Therapy Position Statement Advisory Panel. Menopause. 2017. PubMed
Writing Group for the WHI Investigators. "Risks and benefits of estrogen plus progestin." JAMA. 2002. PubMed
Manson JE, et al. "Menopausal hormone therapy and long-term all-cause and cause-specific mortality." JAMA. 2017. PubMed
Canonico M, et al. "Hormone therapy and venous thromboembolism among postmenopausal women." Circulation. 2007. PubMed
MacLennan AH, et al. "Oral oestrogen and combined oestrogen/progestogen therapy versus placebo for hot flushes." Cochrane Database Syst Rev. 2004. PubMed
Kling JM, et al. "Menopause management knowledge in postgraduate family medicine, internal medicine, and obstetrics and gynecology residents." Mayo Clin Proc. 2019. PubMed
Faubion SS, et al. "Genitourinary syndrome of menopause." Mayo Clin Proc. 2019. PubMed
Allen RH, et al. "Menopausal hormone therapy prescribing patterns." Menopause. 2022. PubMed
Sturdee DW, Pines A. "Updated IMS recommendations on postmenopausal hormone therapy and preventive strategies for midlife health." Climacteric. 2011. PubMed